Eli Lilly Current Ratio 2010-2024 | LLY

Current and historical current ratio for Eli Lilly (LLY) from 2010 to 2024. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Eli Lilly current ratio for the three months ending March 31, 2024 was 1.35.
Eli Lilly Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2024-03-31 $25.19B $18.60B 1.35
2023-12-31 $25.73B $27.29B 0.94
2023-09-30 $23.01B $22.00B 1.05
2023-06-30 $21.33B $18.92B 1.13
2023-03-31 $20.81B $16.01B 1.30
2022-12-31 $18.04B $17.14B 1.05
2022-09-30 $17.64B $15.65B 1.13
2022-06-30 $17.12B $15.62B 1.10
2022-03-31 $16.97B $13.39B 1.27
2021-12-31 $18.45B $15.05B 1.23
2021-09-30 $17.81B $13.68B 1.30
2021-06-30 $17.30B $15.09B 1.15
2021-03-31 $16.61B $11.71B 1.42
2020-12-31 $17.46B $12.48B 1.40
2020-09-30 $16.24B $11.98B 1.36
2020-06-30 $14.58B $11.99B 1.22
2020-03-31 $13.99B $12.61B 1.11
2019-12-31 $13.71B $11.78B 1.16
2019-09-30 $12.66B $10.83B 1.17
2019-06-30 $13.46B $11.86B 1.14
2019-03-31 $12.60B $11.24B 1.12
2018-12-31 $20.55B $11.89B 1.73
2018-09-30 $20.69B $10.83B 1.91
2018-06-30 $18.33B $13.06B 1.40
2018-03-31 $16.26B $11.55B 1.41
2017-12-31 $19.20B $14.54B 1.32
2017-09-30 $17.43B $12.67B 1.38
2017-06-30 $15.75B $11.30B 1.39
2017-03-31 $12.98B $10.45B 1.24
2016-12-31 $15.10B $10.99B 1.38
2016-09-30 $13.39B $8.27B 1.62
2016-06-30 $12.98B $8.40B 1.55
2016-03-31 $11.72B $7.34B 1.60
2015-12-31 $12.57B $8.23B 1.53
2015-09-30 $12.57B $8.30B 1.51
2015-06-30 $12.35B $8.23B 1.50
2015-03-31 $11.74B $8.34B 1.41
2014-12-31 $11.93B $9.74B 1.23
2014-09-30 $12.11B $7.58B 1.60
2014-06-30 $13.16B $7.42B 1.77
2014-03-31 $13.04B $6.63B 1.97
2013-12-31 $13.11B $8.92B 1.47
2013-09-30 $13.20B $8.08B 1.64
2013-06-30 $12.64B $8.41B 1.50
2013-03-31 $12.33B $7.59B 1.62
2012-12-31 $13.04B $8.39B 1.55
2012-09-30 $14.04B $6.96B 2.02
2012-06-30 $12.31B $6.61B 1.86
2012-03-31 $12.60B $6.55B 1.92
2011-12-31 $14.25B $8.93B 1.60
2011-09-30 $14.57B $8.22B 1.77
2011-06-30 $14.95B $8.62B 1.73
2011-03-31 $15.35B $7.65B 2.01
2010-12-31 $14.84B $6.93B 2.14
2010-09-30 $14.18B $6.10B 2.33
2010-06-30 $12.47B $6.33B 1.97
2010-03-31 $12.25B $5.66B 2.17
2009-12-31 $12.49B $6.57B 1.90
2009-09-30 $11.81B $6.07B 1.95
2009-06-30 $10.94B $6.99B 1.57
2009-03-31 $10.26B $7.36B 1.40
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $894.902B $34.124B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Novo Nordisk (NVO) Denmark $632.159B 48.58
Johnson & Johnson (JNJ) United States $363.433B 14.44
Merck (MRK) United States $317.715B 57.81
AbbVie (ABBV) United States $298.785B 15.44
AstraZeneca (AZN) United Kingdom $243.669B 21.18
Novartis AG (NVS) Switzerland $225.923B 16.02
Pfizer (PFE) United States $167.164B 20.77
Sanofi (SNY) $126.763B 11.94
Innoviva (INVA) United States $1.071B 7.52